Pharmadrug Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Robert Steen

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.2yrs
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Robert Steen

1.2yrs

Permanencia

Mr. Robert J. Steen is Chief Executive Officer of Pharmadrug Inc. from September 2023 and was its Chairman since September 2023 until February 2024 and is its Director since February 2024. He has helped fo...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Steen	CEO & Director	1.2yrs	sin datos	sin datos
Terrance Booth	Chairman of Advisory Board	4.4yrs	sin datos	sin datos
Yelena Janjigian	Member of Advisory Board	no data	sin datos	sin datos
David Kideckel	Independent Chairman of the Board	3.3yrs	CA$206.30	sin datos
Paul McClory	Independent Director	7.9yrs	CA$27.46	0.040% € 433.9
Steven Barker	Member of Advisory Board	3.8yrs	sin datos	sin datos
Cindy Hutnik	Member of Scientific & Clinical Advisory Board	2.9yrs	sin datos	sin datos
Jimo Borjigin	Member of Advisory Board	no data	sin datos	sin datos
Zalman Goldman	Director	less than a year	sin datos	sin datos

3.3yrs

Permanencia media

66.5yo

Promedio de edad

Junta con experiencia: La junta directiva de G11 se considera experimentada (3.3 años de antigüedad promedio).

Pharmadrug Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

PharmaDrug Inc Announces Board Changes

Pharmadrug Inc. Announces CFO Changes

Pharmadrug Inc. Announces CFO Changes

PharmaDrug Inc. Announces CEO Changes

Pharmadrug Inc., Annual General Meeting, Oct 23, 2023

High number of new and inexperienced directors

Recent updates

New major risk - Negative shareholders equity

PharmaDrug Inc Announces Board Changes

Pharmadrug Inc. announced that it has received CAD 0.326 million in funding

Pharmadrug Inc. announced that it expects to receive CAD 0.326 million in funding

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Pharmadrug Inc. (CNSX:PHRX) completed the acquisition of Securedose Synthetics Inc.

Pharmadrug Inc. (CNSX:PHRX) entered into a definitive agreement to acquire Securedose Synthetics Inc. for CAD 1.1 million.

Pharmadrug Inc. Announces CFO Changes

Pharmadrug Inc. Announces CFO Changes

PharmaDrug Inc. Provides Development Update of Cepharanthine (PD-001) for Cancer and Infectious Disease

PharmaDrug Inc. Announces CEO Changes

Pharmadrug Inc., Annual General Meeting, Oct 23, 2023

New minor risk - Shareholder dilution

PharmaDrug Inc. Announces Plans for First-In-Human Clinical Study with PD-001 (Enteric-Coated Cepharanthine -2HCL) in Esophageal Cancer

PharmaDrug Advances Programs in Oncology with Filing of Patent Cooperation Treaty Application Detailing the Use of PD-001 for Treatment of Prostate Cancer

Third quarter 2022 earnings released: CA$0.009 loss per share (vs CA$0.004 loss in 3Q 2021)

High number of new and inexperienced directors

Pharmadrug Inc., Annual General Meeting, Nov 22, 2022

Second quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.002 loss in 2Q 2021)

PharmaDrug Advances Psychedelics Pharmaceutical Program Focused on DMT and DMT Analogues

PharmaDrug Completes Key Milestone to Support cGMP Production of Clinical Lead Candidate PD-001

Pharmadrug Inc. announced that it expects to receive CAD 0.65 million in funding

Pharmadrug Inc. Announces Positive Findings for the Combination of Cepharanthine and Frontline Chemotherapy for IND-Enabling Esophageal Cancer Study

Khiron Life Sciences Corp. (TSXV:KHRN) entered into an agreement to acquire Pharmadrug Production GmbH from Pharmadrug Inc. (CNSX:PHRX) for $1.82 Million.

Pharmadrug Inc. announced a financing transaction

Full year 2021 earnings released: CA$0.017 loss per share (vs CA$0.036 loss in FY 2020)

High number of new and inexperienced directors

Pharmadrug Inc. Provides an Update on Multiple Activities Currently Underway Which Support the Company's 'Pipeline-In-A-Pill' Approach in the Development of PD-001

Pharmadrug Inc. Receives Positive Results for DMT-Analogue Program to Treat Glaucoma

PharmaDrug Inc. Announces Filing of US Provisional Patent for Cepharanthine to Treat Prostate Cancer

PharmaDrug Inc. Announces Initiation of Manufacturing of Cepharanthine (PD-001) for Clinical Programs in Rare Cancers and COVID-19

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

High number of new and inexperienced directors

CEO

Permanencia

Miembros de la Junta

Permanencia media

Promedio de edad